In the high-stakes world of biopharmaceutical manufacturing, the bridge between laboratory discovery and commercial-scale production is often fraught with regulatory bottlenecks, technical complexity, and operational friction. FUJIFILM Biotechnologies is currently attempting to redefine this transition, backed by a staggering $7 billion global expansion strategy. At the helm of these operational shifts is Maja Herold Pedersen, who stepped into the role of Chief Operating Officer (COO) in September 2025.
Her transition from Chief Quality Officer to COO signals a fundamental change in how the company views the integration of quality, technology, and speed. By merging the rigid requirements of Good Manufacturing Practice (GMP) with the fluid, rapid evolution of artificial intelligence, Pedersen is attempting to transform the CDMO (Contract Development and Manufacturing Organization) into a decentralized, AI-empowered powerhouse.
The $7 Billion Expansion: A Global Biomanufacturing Footprint
The sheer scale of FUJIFILM’s current infrastructure development is unprecedented in the CDMO sector. The company is not merely adding capacity; it is building an interconnected ecosystem designed to facilitate seamless tech transfers across continents.
Key Infrastructure Milestones:
- Holly Springs, North Carolina: The $3.2 billion flagship site is the crown jewel of the North American strategy. With the first phase operational as of September 2025, the facility is designed for commercial-scale cell culture manufacturing. A second phase is already on the horizon for 2028.
- Hillerød, Denmark: The European hub is undergoing a massive augmentation, integrating eight new 20,000-liter bioreactors alongside two advanced downstream processing streams.
- Teesside, United Kingdom: In early 2026, the company unveiled the UK’s largest single-use CDMO facility, specifically optimized for speed and flexibility in smaller-batch, high-value biologics.
- Madison, Wisconsin: Representing a separate $200 million investment, FUJIFILM Cellular Dynamics opened a new iPSC (induced pluripotent stem cell) headquarters in May 2026, aiming to quadruple production capacity for next-generation cell therapies.
The linchpin of this global network is kojoX, a proprietary modular bioproduction model. By standardizing equipment, quality systems, and processes across all global sites, FUJIFILM aims to ensure that a drug-substance process validated in North Carolina can be transferred to Denmark or the UK with minimal regulatory friction, effectively compressing the time-to-market for clients.
From Quality to Operations: The Pedersen Philosophy
Maja Herold Pedersen’s rise to COO is atypical for the sector, where operations and quality are often siloed. Her background in quality and regulatory affairs provides her with a unique perspective: she views "quality" not as a hurdle to be cleared, but as the essential architecture of patient safety.
"I’ve never been a quality-function-only leader," Pedersen notes. "I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat; we need to make this work for patients in the end."
Her leadership style is characterized by a "boundary-pushing" mentality, encouraged by CEO Lars Petersen. She argues that the traditional pharmaceutical industry tendency to avoid innovation due to validation fears is a dangerous stagnation. Instead, she advocates for a proactive, human-in-the-loop approach to technology.
Industrializing AI: Beyond the Pilot Phase
The most significant operational pivot under Pedersen’s guidance is the move to integrate AI into daily GMP operations. Recognizing that employees were already using external tools like ChatGPT—which posed significant data security risks—Pedersen championed the development of "GenkiBot."
The "Genki" Strategy
Genki (derived from the Japanese concept of vitality and enthusiasm) is an in-house, secure AI ecosystem. It allows employees to leverage generative AI within the company’s strict security perimeter.
- Deviation Management: GenkiBot has been deployed to assist SMEs (Subject Matter Experts) in drafting deviation reports and identifying root causes. By analyzing internal data rather than relying on standard, generic templates, the tool provides context-aware suggestions that improve accuracy.
- Scaling Adoption: Currently, 50% of users involved in deviation management are utilizing the tool. Pedersen’s stated goal is 100% adoption, arguing that AI is no longer optional in a complex biopharma environment.
- Tech Transfer Automation: Looking forward, the company is developing agents capable of "grabbing" data, organizing it into regulatory-compliant formats, and automating the tedious documentation required for technology transfers between sites.
The "Agentic" Future: Setting AI Free
Pedersen’s approach to scaling AI is distinctively counter-intuitive. While most pharmaceutical giants focus on "boxing in" AI with heavy, restrictive guardrails, Pedersen believes in "setting it free" through a democratized funnel.
"I’m a big believer that scaling only follows the actual speed if we set it free," she explains. Her strategy involves equipping individual employees with the coding skills to create their own AI agents. These agents are then tested and, if they prove viable and safe, moved into a controlled enterprise queue for official GMP use.
This model treats the workforce as a decentralized R&D engine. By encouraging the creation of a vast "funnel" of agents, the company can curate the most effective, verified tools for wide-scale deployment. It is an approach that mimics the agility of software development, applied to the highly regulated world of biologics.
Culture as Infrastructure: The 9 People Fundamentals
Technology and expansion are hollow without a robust organizational culture to sustain them. To manage the human element of this growth, Pedersen oversees the implementation of the "9 People Fundamentals."
Empowerment and Accountability
The philosophy centers on the idea of the organization as a living organism. Just as individual cells in a body function autonomously while following a central biological "brain" (the organizational mission), FUJIFILM’s employees are encouraged to make decisions at the point of action.
- Decentralized Decision-Making: By reducing hierarchical bottlenecks, the company aims to release the energy of the individual.
- The "Leaders for Life" Cohort: To support this autonomy, the company is rolling out an intensive training program for leaders. The program focuses on self-awareness, emotional intelligence, and the ability to manage complexity without reverting to rigid, traditional command-and-control structures.
"Being empowered doesn’t come for free," Pedersen admits. "It holds you very accountable for what you’re doing and the moves you make. We’re making things difficult for people in order to make the freedom possible."
Implications for the Future of CDMOs
The transformation at FUJIFILM Biotechnologies serves as a bellwether for the broader pharmaceutical manufacturing industry. The combination of massive physical capacity, modular tech-transfer protocols, and a decentralized AI strategy suggests a new model for global drug production.
Key Takeaways for the Industry:
- Regulatory Speed is a Competitive Advantage: By digitizing the documentation and validation processes through AI, companies can effectively shrink the gap between clinical success and commercial availability.
- Security via Internalization: The development of internal AI ecosystems (like GenkiBot) is essential for companies that want to utilize generative AI without risking the leakage of sensitive intellectual property.
- The New COO Profile: As evidenced by Pedersen, the modern COO of a biotech firm requires a synthesis of quality compliance, operational excellence, and digital literacy. The traditional separation of these roles is becoming a relic of the past.
As the industry faces increasing pressure to produce complex therapies—from monoclonal antibodies to gene-editing tools—the ability to scale operations with human-centric AI and decentralized autonomy will likely separate the market leaders from the rest of the pack. For Maja Herold Pedersen and FUJIFILM, the path forward is clear: build the factory, empower the person, and automate the mundane so that the organization can focus on the mission—getting medicine to patients.
About the Author
